147 related articles for article (PubMed ID: 17804567)
1. Serum eosinophil cationic protein: a marker of disease activity in Churg-Strauss syndrome.
Guilpain P; Auclair JF; Tamby MC; Servettaz A; Mahr A; Weill B; Guillevin L; Mouthon L
Ann N Y Acad Sci; 2007 Jun; 1107():392-9. PubMed ID: 17804567
[TBL] [Abstract][Full Text] [Related]
2. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage.
Schmitt WH; Csernok E; Kobayashi S; Klinkenborg A; Reinhold-Keller E; Gross WL
Arthritis Rheum; 1998 Mar; 41(3):445-52. PubMed ID: 9506572
[TBL] [Abstract][Full Text] [Related]
3. Eotaxin-3 is involved in Churg-Strauss syndrome--a serum marker closely correlating with disease activity.
Polzer K; Karonitsch T; Neumann T; Eger G; Haberler C; Soleiman A; Hellmich B; Csernok E; Distler J; Manger B; Redlich K; Schett G; Zwerina J
Rheumatology (Oxford); 2008 Jun; 47(6):804-8. PubMed ID: 18397958
[TBL] [Abstract][Full Text] [Related]
4. Increased serum high mobility group box-1 level in Churg-Strauss syndrome.
Taira T; Matsuyama W; Mitsuyama H; Kawahara KI; Higashimoto I; Maruyama I; Osame M; Arimura K
Clin Exp Immunol; 2007 May; 148(2):241-7. PubMed ID: 17437420
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic pathway of apoptosis in peripheral blood eosinophils of Churg-Strauss syndrome.
Jakiela B; Szczeklik W; Sokolowska B; Mastalerz L; Sanak M; Plutecka H; Szczeklik A
Rheumatology (Oxford); 2009 Oct; 48(10):1202-7. PubMed ID: 19643727
[TBL] [Abstract][Full Text] [Related]
6. Sputum eosinophilia in Churg-Strauss syndrome.
Meziane H; Maakel ML; Vachier I; Bousquet J; Chanez P
Respir Med; 2001 Oct; 95(10):799-801. PubMed ID: 11601744
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of eosinophil cationic protein levels with clinical symptoms and laboratory findings of patients with cystic echinococcosis].
Cicioğlu Aridoğan B; Kaya S; Sesli Cetin E; Taş T; Demirci M
Mikrobiyol Bul; 2009 Apr; 43(2):285-92. PubMed ID: 19621614
[TBL] [Abstract][Full Text] [Related]
8. Serum eosinophil granule proteins predict asthma risk in allergic rhinitis.
Nielsen LP; Peterson CG; Dahl R
Allergy; 2009 May; 64(5):733-7. PubMed ID: 19133919
[TBL] [Abstract][Full Text] [Related]
9. Serum eosinophilic cationic protein: is there a role in respiratory disorders?
Peona V; De Amici M; Quaglini S; Bellaviti G; Castellazzi AM; Marseglia G; Ciprandi G
J Asthma; 2010 Mar; 47(2):131-4. PubMed ID: 20170318
[TBL] [Abstract][Full Text] [Related]
10. Circulating eosinophils in asthma, allergic rhinitis, and atopic dermatitis lack morphological signs of degranulation.
Malm-Erjefält M; Greiff L; Ankerst J; Andersson M; Wallengren J; Cardell LO; Rak S; Persson CG; Erjefält JS
Clin Exp Allergy; 2005 Oct; 35(10):1334-40. PubMed ID: 16238793
[TBL] [Abstract][Full Text] [Related]
11. Eosinophil activation in preterm infants with lung disease.
Broström EB; Katz-Salamon M; Lundahl J; Halldén G; Winbladh B
Acta Paediatr; 2007 Jan; 96(1):23-8. PubMed ID: 17187598
[TBL] [Abstract][Full Text] [Related]
12. Changes in serum eotaxin and eosinophil cationic protein levels, and eosinophil count during treatment of childhood asthma.
Chu YT; Chiang W; Wang TN; Hung CH; Jong YJ; Wu JR
J Microbiol Immunol Infect; 2007 Apr; 40(2):162-7. PubMed ID: 17446966
[TBL] [Abstract][Full Text] [Related]
13. Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents.
Niccoli G; Schiavino D; Belloni F; Ferrante G; La Torre G; Conte M; Cosentino N; Montone RA; Sabato V; Burzotta F; Trani C; Leone AM; Porto I; Pieroni M; Patriarca G; Crea F
Eur Heart J; 2009 Jun; 30(11):1340-7. PubMed ID: 19383735
[TBL] [Abstract][Full Text] [Related]
14. Serum eosinophil cationic protein in children with atopic dermatitis.
Murat-Susić S; Lipozencić J; Zizić V; Husar K; Marinović B
Int J Dermatol; 2006 Oct; 45(10):1156-60. PubMed ID: 17040428
[TBL] [Abstract][Full Text] [Related]
15. Correlation of eosinophil cationic protein with severity of asthma.
Badar A; Saeed W; Hussain MM; Aslam M
J Ayub Med Coll Abbottabad; 2004; 16(3):66-71. PubMed ID: 15631377
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.
Kim S; Marigowda G; Oren E; Israel E; Wechsler ME
J Allergy Clin Immunol; 2010 Jun; 125(6):1336-43. PubMed ID: 20513524
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome.
Schnabel A; Csernok E; Braun J; Gross WL
Thorax; 1999 Sep; 54(9):771-8. PubMed ID: 10456969
[TBL] [Abstract][Full Text] [Related]
18. Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study.
Zwerina J; Bach C; Martorana D; Jatzwauk M; Hegasy G; Moosig F; Bremer J; Wieczorek S; Moschen A; Tilg H; Neumann T; Spriewald BM; Schett G; Vaglio A
Rheumatology (Oxford); 2011 Oct; 50(10):1823-7. PubMed ID: 21266446
[TBL] [Abstract][Full Text] [Related]
19. The common allergens in the Churg-Strauss syndrome.
Bottero P; Bonini M; Vecchio F; Grittini A; Patruno GM; Colombo B; Sinico RA
Allergy; 2007 Nov; 62(11):1288-94. PubMed ID: 17919144
[TBL] [Abstract][Full Text] [Related]
20. Eosinophilia and thrombophilia in churg strauss syndrome: a clinical and pathogenetic overview.
Ames PR; Margaglione M; Mackie S; Alves JD
Clin Appl Thromb Hemost; 2010 Dec; 16(6):628-36. PubMed ID: 19833618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
